Peri-procedural antithrombotic bridging and the assessment of the associated risk of major bleeding

• References

• 1 Lip GYH, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
• 2 Pisters R, Lane DA, Nieuwlaat R. et al. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
• 3 Camm AJ, Kirchhof P, Lip GY. et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
• 4 Omran H, Bauersachs R, Rubenacker S. et al. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation: Results from the national multicenter BNK Online bRiDging REgistRy (BORDER). Thromb Haemost 2012; 108: 65-73.
• 5 Jamula E, Douketis JD, Schulman S. Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide. J Thromb Haemost 2008; 06: 1615-1621.
• 6 Lip GY, Andreotti F, Fauchier L. et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association (1), endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.
• 7 Jamula E, Lloyd NS, Schwalm JD. et al. Safety of uninterrupted anticoagulation in patients requiring elective coronary angiography with or without percutaneous coronary intervention: a systematic review and metaanalysis. Chest 2010; 138: 840-847.
• 8 Lip GY, Huber K, Andreotti F. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103: 13-28.
• 9 Huber K, Airaksinen KJ, Cuisset T. et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106: 569-571.
• 10 Faxon DP, Eikelboom JW, Berger PB. et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 572-584.
• 11 Lakkireddy D, Reddy YM, Di Biase L. et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2012; 59: 1168-1174.
• 12 Winkle RA, Mead RH, Engel G. et al. The Use of Dabigatran Immediately After Atrial Fibrillation Ablation. J Cardiovasc Electrophysiol 2012; 23: 264-268.
• 13 Lip GY, Frison L, Halperin JL. et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57: 173-180.
• 14 Gallego P, Roldan V, Torregrosa JM. et al. Relation of the HAS-BLED Bleeding Risk Score to Major Bleeding, Cardiovascular Events, and Mortality in Anti-coagulated Patients With Atrial Fibrillation. Circulation Arrhyth Electrophysiol 2012; 05: 312-318.
• 15 Roldan V, Marin F, Manzano-Fernandez S. et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a ‘real world’ anticoagulated atrial fibrillation population. Chest. 2012 in press.